,32 The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) was a randomised, double-blind study, that evaluated the possible role of omalizumab (>600 mg every 2 or 4 weeks) in the management of severe paediatric AD for 24 weeks.30 This evidence concerns the gene IGHE and atopic eczema.